Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile8 entries
2021
Novartis and Dana-Farber sue Dr. Reddy’s over generic Rydapt
Lawsuit filed
Novartis Pharmaceuticals and Dana-Farber Cancer Institute filed a complaint alleging that Dr. Reddy’s Laboratories infringed Novartis’s patent for Rydapt through its proposed generic leukemia treatment. The allegations are claims in the lawsuit, not a court finding.
Source excerpt
On Friday, Novartis Pharmaceuticals and Dana-Farber Cancer Institute Inc. filed a complaint against fellow pharmaceutical company Dr. Reddy’s Laboratories Inc. in the District of New Jersey. The plaintiff alleged that the defendant is infringing on its patent for the drug Rydapt, used to treat leukemia.
2021
Dr. Reddy's recalls prescription drug blister packages
Recall announced
Dr. Reddy's recalled approximately 21,400 blister packages of specified prescription medications because the packaging was not child resistant and could pose a poisoning risk if young children swallowed the contents. No incidents or injuries had been reported.
Company response
Refund or compensation — Dr. Reddy's
Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
Source excerpt
Units: About 21,400
WASHINGTON, Feb. 25, 2021 /PRNewswire/ -- https://cpsc.gov/Recalls/2021/Dr-Reddys-Recalls-Prescription-Drug-Blister-Packages-Due-to-Risk-of-Poisoning
Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.
2020
Dr. Reddy’s recalls Esomeprazole Magnesium capsules
Recall announced
Dr. Reddy’s Laboratories voluntarily recalled 1,752 bottles of generic Esomeprazole Magnesium delayed-release capsules in the United States. According to the report, the recall followed the USFDA's identification of discoloration and brown pellets in the product. The report describes the action as a Class III recall.
Dr. Reddy’s is voluntarily recalling 1,752 bottles of generic Esomeprazole Magnesium delayed-release capsules in the US after the USFDA identified discoloration and brown pellets in the product. The report says it is a Class III recall.
Source excerpt
According to a US Food and Drug Administrationâs (USFDA) report, the recall by the Hyderabad-based company is due to âDiscolourationâ and presence of brown pellets in the product.
As per USFDA norms, the recall has been classified as Class III according to which the product is ânot likely to cause adverse health consequencesâ.
Pharma major Dr Reddyâs Laboratories Ltd has initiated recall of 1m752 bottles of generic Esomeprazole Magnesium delayed release capsules in the US.
2020
Dr. Reddy's and Celgene settle Revlimid patent litigation
Settlement
Dr. Reddy's Laboratories announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy's to sell volume-limited generic lenalidomide capsules in the United States beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026. The announcement described the licensed sales as volume-limited until the later date, when the volume limitation would no longer apply.
Dr. Reddy’s announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy’s to sell volume-limited generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026.
Source excerpt
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval.
Dr. Reddy's is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries (together referred to as "Dr. Reddy's"), today announced the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.
2020
Dr. Reddy's Laboratories discloses ransomware attack
Issue disclosure
Dr. Reddy's Laboratories stated that the cyber attack it had detected the previous week involved ransomware. The company said it had isolated the impacted IT services. It also said its investigation had not determined whether any data breach involved personally identifiable information.
Dr. Reddy’s Laboratories said the cyber attack it had detected the previous week involved ransomware. The company said it had isolated impacted IT services and that its investigation had not determined whether any data breach involved personally identifiable information.
Company response
Investigation — Dr. Reddy’s Laboratories
Following the incident, the company said it had engaged leading outside cybersecurity experts and launched a comprehensive containment and remediation effort as well as investigation to address the incident.
Remediation — Dr. Reddy’s Laboratories
Following the incident, the company said it had engaged leading outside cybersecurity experts and launched a comprehensive containment and remediation effort as well as investigation to address the incident.
Source excerpt
Dr. Reddyâs Laboratories on Wednesday said the cyber attack it had detected on last week involved a ransomware attack.
2019
Court denies Dr. Reddy’s summary judgment motion in VIMOVO patent litigation
Ruling
The United States District Court for the District of New Jersey denied a motion for summary judgment filed by Dr. Reddy’s Laboratories in Nuvo-related litigation over two VIMOVO patents, so the patent infringement litigation would continue. Nuvo said it believed the patents were valid and enforceable; the court decision reported here concerned the motion, not a final determination of infringement.
Source excerpt
today announced that the United States District Court for the District of New Jersey has denied a motion for summary judgment filed by Dr. Reddy's Laboratories Inc. (DRL). As a result, the patent infringement litigation against DRL, involving Nuvo Pharmaceuticals (Ireland) DAC's (Nuvo Ireland) U.S. Patent Nos. 8,858,996 and 9,161,920 (the '996 and '920 patents), will continue.
We believe these patents are valid and enforceable and will continue to enforce Nuvo Ireland's rights against DRL.
2019
Dr. Reddy's recalls ranitidine lots in the US
Recall announced
Dr. Reddy's initiated a voluntary recall of several lots of its ranitidine products in the US after confirmed contamination with NDMA above levels established by the FDA. The recall began on October 1.
Source excerpt
The recall has been initiated at the retail level for over-the-counter products and at the consumer level for prescription products of all of its ranitidine medications sold in the US due to confirmed contamination with NDMA above levels established by the USFDA, Dr Reddy's said in a filing to the BSE.
Pharma major Dr. Reddyâs Laboratories is recalling all of its ranitidine medications sold in the U.S. due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above the levels established by the U.S. Food and Drug Administration (USFDA).
Dr Reddy's Laboratories on Wednesday said it has initiated a voluntary nationwide recall of all its ranitidine medications sold in the US due to contamination with probable cancer causing N-Nitrosodimethylamine (NDMA).
1995
Russian joint-venture controversy
Dr. Reddy's exited its Russian joint venture with Biomed amid reported allegations involving a significant material loss and activities connected with the Moscow branch and Biomed's chief executive. The venture was subsequently sold to the Sistema group.